业绩总结 - 2024年第二季度收入增长12%，达到1.65亿美元[89] - 调整后毛利润增长20%，达到7800万美元[90] - 调整后EBITDA增长630%，达到1100万美元[94][96] - 第二季度总净收入为1.645亿美元，同比增长12%[114] - 调整后的毛利润为7780万美元，同比增长20.1%[114] - 调整后的EBITDA为1090万美元，同比增长629.9%[114] - GAAP总收入为164,502百万，同比增长12.0%；六个月为320,742百万，同比增长12.9%[149] 用户数据 - 临床收入增长15%，达到1.41亿美元，测试每次收入增长9%至454美元[99][106] - NGS（下一代测序）增长约40%，占临床收入的30%[92] - 高级诊断收入同比下降3%，但较2024年第一季度增长6.5%[111] - 公司实现连续第13个季度的每次测试收入增长[105] 财务状况 - 现金及现金等价物为3.551亿美元，较上年末增加1.63%[120] - 总资产为16.433亿美元，较上年末下降1.4%[120] - 总负债为7.274亿美元，较上年末下降0.6%[120] 未来展望 - 2024财年收入指导为6.55亿至6.67亿美元，同比增长11%至13%[126] - 2024财年调整后EBITDA指导为2100万至2400万美元，同比增长600%至700%[127] 成本与利润 - 调整后的收入成本（非GAAP）为$73,542百万，同比增长9.0%；六个月为$145,779百万，同比增长11.7%[146] - GAAP毛利润为$63,294百万，同比增长23.1%；六个月为$120,985百万，同比增长22.2%[146] - GAAP毛利率为44.8%，较去年同期的41.7%上升[147] - 调整后的毛利润（非GAAP）为$77,761百万，同比增长20.1%；六个月为$148,535百万，同比增长19.4%[150] 亏损情况 - GAAP净亏损为$18,642百万，较去年同期的$24,331百万有所改善[152] - 调整后的净亏损（非GAAP）为$3,000百万，较去年同期的$9,000百万有所改善[160] - 调整后的稀释每股收益（非GAAP）为$0.02，较去年同期的$0.07有所下降[160]

财务业绩 - 第二季度收入增长12%至1.65亿美元[4] - 临床服务收入增长15%至1.41亿美元[4] - 高级诊断收入下降3%至2,311万美元[4] - 2024年上半年总收入为3.207亿美元，同比增长12.9%[47] - 临床服务业务2024年上半年收入为2.759亿美元，同比增长15.9%[39] - 先进诊断业务2024年上半年收入为4,482万美元，同比下降2.8%[43] - 公司2024年上半年GAAP毛利润为1.38亿美元，同比增长20.3%[5] - 公司2024年上半年非GAAP调整后毛利润为1.49亿美元，同比增长19.4%[5] 盈利能力 - 净亏损下降23%至1,900万美元[7] - 经调整EBITDA增长630%至正11百万美元[8] - 临床服务业务2024年上半年调整后毛利率为47.2%，同比提升1.6个百分点[42] - 先进诊断业务2024年上半年调整后毛利率为41.0%，同比提升4.4个百分点[46] - 公司2024年上半年GAAP毛利率为43.0%，同比提升2.6个百分点[50] - 公司2024年上半年非GAAP调整后毛利率为46.3%，同比提升2.5个百分点[50] - 公司2024年第二季度GAAP净亏损为1864.2万美元，同比减亏27.8%[55] - 公司2024年第二季度非GAAP调整后净亏损为442.4万美元，同比减亏166.1%[55] - 公司2024年第二季度非GAAP调整后每股盈利为0.03美元，同比扭亏为盈[56] 运营指标 - 第二季度临床检测量增长6%[4] - 临床检测平均收入增长9%至454美元[4] - 2024年上半年调整后EBITDA为1,436万美元，去年同期为亏损916.7万美元[37] - 2024年第二季度调整后EBITDA为1,086.9万美元，去年同期为亏损205.1万美元[37] 财务状况 - 2024年上半年现金及现金等价物余额为3.551亿美元，较2023年年初增加9,190.8万美元[31] - 2024年上半年资本性支出为1,866.3万美元，同比增加7.1%[31] - 2024年上半年调整后净亏损为4,570.3万美元，去年同期为5,512.6万美元[37] - 公司2024年第二季度临床检测服务业务成本包括400万美元的无形资产摊销和20万美元的股票激励费用[51] - 公司2024年第二季度先进诊断业务成本包括60万美元的无形资产摊销和10万美元的股票激励费用[51] - 公司2024年第二季度GAAP每股亏损为0.15美元，同比减亏21.1%[56] 业务展望 - 全年收入指引上调至6.55亿至6.67亿美元[9] - 全年经调整EBITDA指引上调至3,300万至3,700万美元[9]

TORONTO, July 26, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) New Collaboration Agreement with Australia-Based Solar PV Recycler – Lotus Energy Recycling Lotus Energy: Proprietary Recycling Technology Know-How to Produce High-Purity 99.9% Recycled PV SiliconTo Reach 3,600 kg Per Annum Scale in 2024 and Expansion to 120,000 kg Per Annum Subsequently Planned in Each of Melbourne, Sydney, and Germany by 2026 Will Explore Joint Venture Opportunities for North American Footprint in Silicon Recycling Will A ...

FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1 marker.Trial expands from patients afflicted with Recurrent Grade IV Astrocytoma with IDH1 mutation to those with equally aggressive Recurrent Grade III Astrocytoma with IDH1 mutation.Enrollment in three other NeOnc clinical studies also advance after several published studies indicate the viability of NeOnc’s NEO™ platfo ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) -- (TSXV: NBM) (OTC: NBMFF) Collaboration Agreement with INNOX eco-M – Leading South Korean Chemical Material Company of Recycled Silicon Powders Subsidiary of INNOX Holding Corp. – A Producer of Secondary Battery Materials and IT High-Tech Materials with Investment Business Operations Jointly Developing Silicon Anode Products with INNOX eco-M’s High-Purity Recycled Silicon Development Priorities: Enhance Electrochemical Performance, Lower Anode Manufacturing Costs & ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Kendra Sweeney - VP of IR Chris Smith - CEO Jeff Sherman - CFO Warren Stone - Chief Commercial Officer Melody Harris - Chief Operations Officer and President, Informatics Ali Olivo - EVP, General Counsel and Business Development Conference Call Participants Mark Massaro - BTIG Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Andrew Brackman - William Blair Tejas Savant - Morgan Stanley Mike M ...

For the quarter ended March 2024, NeoGenomics (NEO) reported revenue of $156.24 million, up 13.9% over the same period last year. EPS came in at -$0.02, compared to -$0.09 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $149.82 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.03.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

NeoGenomics (NEO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post a loss of $0.01 per share when it actually produced earnings of $0.03, delivering a surprise of 400%.Over the last four ...